Amgen Faces Revenue Pressure as Stelara Biosimilars Enter Market
PILLAR DIAGNOSTIC // WEEK 13
“A hard external ceiling from incoming Stelara biosimilars is set to cut immunology revenue growth, while robust machine‐driven top‐line forecasts haven’t fully reflected this headwind, creating a latent repricing risk as the patent cliff approaches.”
Proposed action
Hedge downside risk or trim existing positions; avoid adding to longs ahead of the biosimilar‐driven headwind.
THE MECHANICS
Tape & flow
—
THE MACHINE
Operational momentum
Revenue growth is projected at +4.4% to $8.51 billion this quarter and full-year sales near $37.9 billion, with Q4 adjusted EPS of $5.29 topping estimates though next-quarter EPS is forecast to decline about 3.3%. A robust late-stage pipeline of high-margin, first-in-class therapies underpins expectations for top-line growth and margin expansion over the coming years.
THE MAP
Structure & constraints
Patent expirations and licensing deals are ushering in Stelara biosimilars in 2025, driving a 10.4% segment contraction, while intensifying drug pricing pressure and biosimilar rivalry impose external constraints on franchise growth; concurrently, emerging therapies such as CD20, BAFF/APRIL, and next-generation complement inhibitors signal potential threefold expansion in the myasthenia gravis market within a competitive landscape dominated by major biopharma players.
THE MOOD
Consensus & positioning
Investors are exercising caution with Hold/Equal-Weight ratings while valuing Amgen near fair value; they note strong innovation credentials, acknowledge a slight earnings decline, and still view the stock as undervalued based on long-term cash flow expectations.